To provide greater understanding of the "real world" effect of anticoagulation on stroke risk over several years. DESIGN: Cohort study. SETTING: Anticoagulation and Risk Factors in Atrial Fibrillation Study community-based cohort. PARTICIPANTS: Adults with nonvalvular atrial fibrillation (AF) between 1996 and 2003 (13,559). MEASUREMENTS: All events were clinician adjudicated. Extended Cox regression with longitudinal warfarin exposure was used to estimate cause-specific hazard ratios (HRs) for thromboembolism and the competing risk event (all cause death). The Fine and Gray subdistribution regression approach was used to estimate this association while accounting for competing death events. As a secondary analysis, follow-up was limited to 1, 3, and 5 years. RESULTS: The rate of death was much higher in the group not taking warfarin (8.1 deaths/100 person-years (PY)) than in the group taking warfarin (5.5 deaths/100 PY). The cause-specific HR indicated a large reduction in thromboembolism with warfarin use (adjusted HR = 0.57, 95% confidence interval (CI) = 0.50-0.65), although this association was substantially attenuated after accounting for competing death events (adjusted HR = 0.87, 95% CI = 0.77-0.99). In analyses limited to 1 year of followup, with fewer competing death events, the results for models that did and did not account for competing risks were similar. CONCLUSION: Analyses accounting for competing death events may provide a more-realistic estimate of the longerterm stroke prevention benefits of anticoagulants than traditional noncompeting risk analyses for individuals with AF, particularly those who are not currently treated with anticoagulants. J Am Geriatr Soc 65:35-41, 2017.
A trial fibrillation (AF) is independently associated with approximately five times the risk of ischemic stroke and is estimated to account for 15% of all strokes nationally, including more than 36% of strokes in individuals age 80 and older. 1, 2 Warfarin anticoagulation therapy markedly reduces risk of ischemic stroke in individuals with AF. [3] [4] [5] Studies examining the association between warfarin therapy and incidence of ischemic stroke have not formally taken competing risks into account. A competing risk is an event whose occurrence precludes the ability to observe the outcome of interest for reasons such as dying from another cause. 6 Given that the prevalence of AF is strongly associated with older age, rising to nearly 10% of individuals aged 80 and older, deaths from comorbid conditions are common. 7, 8 Accounting for competing risks may provide greater understanding of the long-term, real-world effect of AF on stroke risk and the expected preventative effect of anticoagulation in adults with AF.
Time-to-event statistical approaches such as KaplanMeier survival analysis and Cox proportional hazards regression are standard approaches that account for unequal follow-up time for participants based on different censoring events. Most often, competing risk events are ignored in these analyses, but ignoring competing risks may result in overestimates of the incidence of the outcome of interest. 6, 9, 10 Individuals with AF not taking warfarin are more likely to be elderly and frail and have higher rates of death than those taking warfarin. 11 As a result, estimates of the longer-term effect of starting anticoagulants in individuals with AF not taking warfarin in usual clinical care may be particularly biased if competing risks are not taken into account. 11 This study aimed to assess the effect of accounting for competing risk events when estimating the effect of warfarin anticoagulation on prevention of thromboembolism in a population of individuals with AF in clinical care.
METHODS

Source Population
Assembly of the Anticoagulation and Risk Factors in Atrial fibrillation (ATRIA) cohort has been described in detail. 12 In brief, the cohort included 13,559 adults aged 18 and older with diagnosed nonvalvular AF who received care from Kaiser Permanente Northern California. 5 Cohort members were identified by searching electronic inpatient, outpatient, and electrocardiographic databases for physician-assigned International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes of AF (427.31, 427.32) between July 1996 and December 1997. All individuals aged 18 and older with two or more outpatient AF diagnoses or one outpatient AF diagnosis with electrocardiographic validation were included. Included individuals were followed through September 2003. Because the study was interested in nontransient, nonvalvular AF, individuals with AF with diagnosed mitral stenosis, valvular repair or replacement, transient postoperative AF, or concurrent hyperthyroidism were excluded. All participants were followed prospectively from their index date (date of the first diagnosis of AF during the period of cohort assembly) until the event of interest, a competing risk event, withdrawal from the health plan, or end of follow-up.
Measures
Longitudinal warfarin exposure was assessed using an algorithm validated by chart review based on the number of days supplied per dispensed warfarin prescription from health plan pharmacies and intervening outpatient international normalized ratio measurements. 12 The outcome of interest was thromboembolism. Thromboembolism included ischemic stroke and systemic arterial embolism and was identified by searching hospitalization and billing claims databases for relevant ICD-9-CM codes found in the primary discharge diagnosis position. 5 A valid ischemic stroke was defined as a documented acute neurological deficit fitting a vascular distribution and lasting more than 24 hours that was not explained by other causes (e.g., primary hemorrhage, trauma, infection, vasculitis). A valid peripheral embolism was defined as an acute occlusion identified by radiographic imaging, intraoperative examination, or pathological findings in the absence of underlying atherosclerotic disease in the affected artery. A clinical outcomes committee composed of physicians adjudicated potential events using a structured medical records review. Only a participant's first valid thromboembolism event was included in the analysis.
Deaths from any nonthromboembolism cause were considered competing risk events. Thromboembolismrelated deaths were not considered competing events because subjects who died from a thromboembolism experienced the event of interest before death. Deaths were determined by reviewing medical charts, health plan databases, Social Security Administration vital status files, and the comprehensive California State death certificate registry.
Information on participant characteristics, including age (<65, 65-74, 75-84, ≥85), sex, and self-reported race and ethnicity (white, black, Asian and Pacific Islander, Hispanic, other or unknown), was obtained from administrative databases. Information on history of comorbid conditions, including prior ischemic stroke, heart failure, coronary heart disease, peripheral artery disease, hypertension, and diabetes mellitus was collected from clinical inpatient and ambulatory databases and pharmacy dispensing data using validated algorithms, assessed using data from the 5 years before the participant's index date, and updated during follow-up. 8, 12 Kidney dysfunction (defined as estimated glomerular filtration rate (eGFR) <45 mL/min per 1.73 m 2 ) was calculated from outpatient serum creatinine values using the Chronic Kidney Disease Epidemiology (CKD-EPI) Collaboration formula. 13 Participants without eGFR measured in the prior year were considered to have normal renal function, and participants undergoing dialysis were considered to have kidney dysfunction. Proteinuria was defined as a urine dipstick protein result of 1+ or greater (≥30 mg/dL) in the absence of potential urinary tract infection found in laboratory databases.
14 Participants without a urine dipstick protein laboratory result in the prior year were considered not to have proteinuria. All health-related variables were dichotomized. CHADS 2 , 15 CHA 2 DS 2 -VASc, 16 and ATRIA 17 stroke risk scores were calculated for all participants.
Statistical Analysis
Two of the most commonly used approaches to competing risk regression differ in construction of the risk set. The cause-specific hazard is estimated by constructing a proportional hazards model separately for each event type, with individuals who experience the competing event type treated as censored observations. In this situation, the risk set is modified over time by removing individuals from remaining risk sets as they have either event, so the competing event influences the measure of association for the event of interest by removing at-risk person-time from the risk set over time. 18 Alternatively, a regression modeling approach has been developed for competing-risk analysis that is a modification of the Cox proportional hazards model and measures the subdistribution cumulative incidence function. 10 This method considers the effect of predictors on the subdistribution hazard function, accounting for the presence of competing risks. 10 In contrast to the causespecific hazard, with individuals who have a competing event censored, in the subdistribution hazard model, these individuals remain in the risk set but can never experience the event of interest. 18, 19 The subdistribution hazard is then defined as the probability of the event of interest given that an individual has survived up to that time without having the event of interest or has had the competing event before that time. 18 The cause-specific and subdistribution approaches are both informative. The cause-specific hazard approach addresses the potential etiological association between an exposure and an event, and the subdistribution hazard approach seeks to demonstrate the actual benefit of an exposure or treatment in a given population. 20 Distributions of each covariate were assessed according to exposure status (warfarin use) and according to the occurrence of outcome events (thromboembolism events). The rates of thromboembolism events and death were also calculated according to warfarin status. Extended Cox regression was used to estimate unadjusted and adjusted cause-specific incidence rate ratios for the outcome of interest (thromboembolism events) and the competing risk event (death), accounting for different lengths of follow-up or participants and time-varying exposure status while adjusting for time-varying potential confounders. The subdistribution hazard modeling approach was then used, and the result was compared with the results for the outcome of interest from the cause-specific hazard models. 10 The unadjusted cumulative incidence for the cause-specific model was plotted using an approach that uses KaplanMeier product-limit calculations for time-varying covariates 21, 22 and using an extension of Cox regression for the subdistribution hazards model. 10 All deaths occurring in subjects who did not experience a thromboembolism event during follow-up were considered competing risk events. As a secondary analysis, follow-up was limited to 1, 3, and 5 years to have fewer competing risk events. In addition, to examine the effect of competing risks in different age groups, an interaction term between age and warfarin use was added to generate cause-specific and subdistribution hazard ratios (HRs).
The institutional review boards at Massachusetts General Hospital and Kaiser Foundation Research Institute approved this research. Waiver of informed consent was obtained because of the nature of the study.
RESULTS
Follow-Up and Characteristics of the Study Population
Participants were followed for an average of 4.77 years (median 5.9 years, interquartile range 2.7-6.7 years). Participants not using warfarin were more likely to be younger than 65 and aged 85 and older than participants using warfarin at baseline. In contrast, participants using warfarin were more likely to have traditional AF stroke risk factors, including prior ischemic stroke, diabetes mellitus, coronary artery disease, hypertension, and heart failure ( Table 1) . As a result, participants using warfarin had higher mean CHADS 2 (2.02 vs 1.64), CHA 2 DS 2 -VASc (3.68 vs 3.22), and ATRIA (6.65 vs 5.89) stroke risk scores at baseline than those not using warfarin. Over the same period, there were 1,092 thromboembolism events (1,017 ischemic strokes, 75 systemic arterial emboli), with 407 occurring in those taking warfarin (1.3/ 100 PY) and 685 occurring in those not taking warfarin (2.1/100 PY) (RR = 0.60, 95% CI = 0.53-0.68). Figure 1a displays the estimated cumulative incidence of thromboembolism in those taking and not taking warfarin from the cause-specific model. The adjusted cause-specific HR for thromboembolism was 0.57 (95% CI = 0.50-0.65), reflecting a much lower stroke rate with warfarin (Table 2 ). In the subdistribution hazard models that account for competing death events, the lower rate of thromboembolism associated with warfarin was markedly attenuated in unadjusted (HR = 0.84, 95% CI = 0.74-0.95) and adjusted (HR = 0.87, 95% CI = 0.77-0.99) models (Table 2 ). This attenuated effect of warfarin due to competing death events is further demonstrated in the cumulative incidence curves estimated using the subdistribution hazards model (Figure 1b 
In analyses limited to 1 year of follow-up, there were 648 competing death events. Mortality in those taking and not taking warfarin were lower than in longer-term follow-up. Mortality in the warfarin group (4.3/100 PY) was lower than in those not taking warfarin (5.6/100 PY) (RR = 0.77, 95% CI = 0.66-0.90) ( Table 3 ). In the first year of followup, there were 294 thromboembolism events. The rate of thromboembolism in this 1-year period was lower in those taking warfarin (1.7/100 PY) than in those not taking warfarin (2.8/100 PY). Similar to the full follow-up period, the SDH on warfarin SDH off warfarin CSH on warfarin CSH off warfarin Cumulative Incidence Figure 1 . Unadjusted cumulative incidence curves estimated using (a) the Simon and Makuch approach (cause-specific model) 22 and (b) the subdistribution hazards modeling approach for individuals taking and not taking warfarin. Unadjusted cumulative incidence at the end of follow-up is higher for individuals not taking warfarin in the cause-specific model than in the subdistribution hazards model, and cumulative incidence curves for individuals taking and not taking warfarin are closer together in the subdistribution hazards model. In the cause-specific model, individuals who have a competing death event are censored and assumed to be at risk for the outcome, despite the outcome no longer being possible. In the subdistribution hazards model, individuals with a competing death event remain in the risk set but can never experience the event of interest. The unadjusted curves for the subdistribution modeling approach were generated with the assumption of proportional hazards.
cause-specific RR and HR during 1 year of follow-up indicated a markedly lower risk of thromboembolism for those taking warfarin than for those not using warfarin in unadjusted (RR = 0.61, 95% CI = 0.48-0.77) and adjusted (HR = 0.55, 95% CI = 0.43-0.71) analyses. With many fewer competing death events and more-similar mortality in those taking and not taking warfarin during the first year of follow-up, the subdistribution HR during this period was similar to the cause-specific HR in unadjusted (HR = 0.64, 95% CI = 0.51-0.82) and adjusted analyses (HR = 0.59, 95% CI = 0.46-0.75) ( Table 3) . As the number of competing death events increased over time (3 years: 2,266 deaths; 5 years: 3,503 deaths) and the difference in mortality in those not taking and taking warfarin grew, the adjusted subdistribution HR moved toward the markedly attenuated association observed over the full 7 years of follow-up (Table 3) .
Warfarin Use and Thromboembolism by Age Group
The difference between the cause-specific HR and the subdistribution HR is greater among older age groups, indicating a bigger impact of competing death events among older adults (Table 4) .
DISCUSSION
Within a large community-based cohort of individuals with nonvalvular AF in clinical practice followed for up to 7 years, warfarin was associated with a lower rate of thromboembolism in cause-specific hazard models that did not account for competing risk events. These long-term, real-world results extend earlier findings and are consistent with those of randomized trials conducted for a shorter period of time with participants who meet strict eligibility criteria. 3, 5 The protective association between warfarin and thromboembolism was markedly attenuated over the full follow-up period when using a modeling approach that accounted for the large number of competing death events that occurred and the substantially higher death rate in participants not taking warfarin. When analyses were limited to 1 year of follow-up with many fewer competing Adjusted for age, sex, race, prior stroke, diabetes mellitus, coronary disease, peripheral artery disease, hypertension, significant kidney dysfunction, proteinuria. PY = person years; aHR = adjusted hazard ratio; CI = confidence interval. death events, models that did and did not account for competing death events produced similar results and demonstrated a strong protective effect of warfarin against thromboembolism events. Furthermore, the results demonstrate that the effect of competing death events is greatest in older adults, in whom death rates are higher. Large fractions of individuals with AF do not undergo anticoagulant therapy. 23 The authors of the current study were interested in estimating the potential stroke-preventive effect of anticoagulating ATRIA cohort participants not receiving warfarin. In contrast to randomized trials, individuals with AF in clinical care have a high rate of competing death events over long-term follow-up, consistent with their older age (45% aged ≥75) and comorbidity burden. Competing death events (4,414 deaths) were much more numerous than thromboembolic events (1,092 thromboembolism events) and occurred more frequently in those not taking warfarin (8.1/100 PY) than in those taking warfarin (5.5/100 PY). Although the cause-specific hazard approach demonstrated a strong effect of warfarin, the subdistribution hazard approach accounting for competing death events provides a more-realistic population-level estimate of the stroke-preventive benefit of warfarin therapy over a long follow-up period in predominantly older adults with AF in clinical care. In particular, these results highlight the lower expected long-term benefit of anticoagulant therapy in individuals not currently taking anticoagulants. Older age, comorbidity, and frailty are among the reasons individuals with AF are not treated with anticoagulants, and these features are reflected in higher mortality. [23] [24] [25] When limiting the follow-up to 1 year, there were far fewer competing death events, mortality in the warfarin and nonwarfarin groups were more similar, and the results that did and did not account for competing risks were comparable. The cause-specific results remained essentially constant between 1-year and full follow-up, demonstrating a large protective effect of warfarin, but the competing risk analysis produced progressively smaller effects of warfarin.
Guidelines recommend use of anticoagulants in individuals with AF based on untreated risk of stroke. 26, 27 As this risk increases, the expected reduction in absolute stroke risk increases in parallel, 28 but this benefit of anticoagulants is contingent upon survival. In predominantly older adults with AF, the competing risk of death reduces the expected longer-term benefit of anticoagulants. In realworld clinical care, the oldest adults with comorbid illness and frailty are less likely to be treated. Estimates of the individual-or population-level benefit of adding an anticoagulant to these currently untreated individuals is more realistically estimated by competing risk analyses. Recent research has used competing risk analyses to assess stroke risk in individuals with AF with end-stage renal disease, a population with high rates of competing death events. 29 These analyses view nonthromboembolic deaths as competing risk events. One concern is that warfarin reduced the risk of these competing events as well. The original warfarin AF trials found lower all-cause death in the warfarin arms, 30 but in the later Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA) in elderly adults with AF, which also demonstrated marked lower stroke risk with warfarin than aspirin, there was no difference in overall mortality, and BAFTA had more nonstroke vascular deaths in the warfarin arm. 31 More recently, the Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment trial demonstrated 55% lower stroke risk with the oral anticoagulant apixaban than with aspirin but with only slightly lower nonstroke mortality risk. 32 Taken together, this evidence from randomized trials indicates that most of the large relative and absolute differences in nonstroke mortality observed between individuals using and not using warfarin are independent of warfarin's effect.
Examination of a large cohort of individuals with AF with long-term comprehensive follow-up and a large number of outcome events strengthened this study. Physicians adjudicated all thromboembolism events using a standardized medical record review protocol. Competing death events were ascertained from multiple comprehensive databases, and is expected that ascertainment was complete. Longitudinal warfarin exposure was assessed using a validated algorithm that uses comprehensive pharmacy and laboratory databases.
This study also has several potential limitations. There may be residual confounding in the comparative analyses of stroke rates despite controlling for all the risk factors included in the CHADS 2 , CHA 2 DS 2 -VASc, and ATRIA stroke risk scores. Information was not available on aspirin use for individuals not prescribed warfarin, so the nonwarfarin group included a mix of individuals taking and not taking aspirin. The search strategy may have missed a small number of thromboembolism events that did not lead to hospitalization, although it is not expected that these missed events differed according to warfarin status. Finally, cause of death was known only for hospitalized thromboembolism and bleeding events and not for the vast majority of competing death events.
In conclusion, this study demonstrates the large effect of accounting for competing death events when evaluating the longer-term stroke prevention effect of anticoagulants in individuals with AF in clinical care. The competing risk of death is common in individuals with AF and is higher than the risk of thromboembolism events. Furthermore, mortality of individuals not prescribed anticoagulants is markedly higher than of individuals taking warfarin, reflecting the higher proportion of elderly adults and those with complex comorbidities among individuals not prescribed warfarin. As a consequence, analyses accounting for competing death events result in a smaller estimated effect of warfarin than standard cause-specific approaches that treat deaths as censoring events, and the difference increases with length of follow-up. The cause-specific HR can provide a valid estimate of the etiological effect of anticoagulants in individuals with AF, although it is likely that the competing risk analyses presented in this study provide a more-realistic estimate of the longer-term strokereducing benefits of warfarin for individuals with AF not currently being anticoagulated in clinical care. The strokepreventive benefits of anticoagulation for individuals with AF accumulate over time. For healthcare system quality improvement programs, the analyses emphasize the importance of encouraging use of anticoagulants in individuals with AF in relatively good health. For clinicians and individuals, these analyses highlight the importance of accounting for the individual's life expectancy in weighing the benefits and harms of long-term anticoagulant therapy.
